Sinotherapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100005PL9
CNY
7.26
-0.28 (-3.71%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Sinotherapeutics, Inc.

Why is Sinotherapeutics, Inc. ?

1
High Debt Company with a Debt to Equity ratio (avg) at times
  • Poor long term growth as Net Sales has grown by an annual rate of 21.00% and Operating profit at 19.25% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
  • The company has been able to generate a Return on Equity (avg) of 10.64% signifying low profitability per unit of shareholders funds
2
With a fall in Net Sales of -12.82%, the company declared Very Negative results in Sep 25
  • NET SALES(Q) At CNY 111.86 MM has Fallen at -12.82%
  • INTEREST COVERAGE RATIO(Q) Lowest at 2,713,996.62
  • OPERATING PROFIT(Q) Lowest at CNY 13.01 MM
3
Below par performance in long term as well as near term
  • Along with generating -10.11% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sinotherapeutics, Inc. for you?

Medium Risk, Low Return

Absolute
Risk Adjusted
Volatility
Sinotherapeutics, Inc.
-28.26%
0.41
32.54%
China Shanghai Composite
16.78%
1.58
14.20%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
8.01%
EBIT Growth (5y)
-5.93%
EBIT to Interest (avg)
54.21
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.57
Sales to Capital Employed (avg)
0.35
Tax Ratio
9.90%
Dividend Payout Ratio
33.08%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.52%
ROE (avg)
10.64%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
85
Industry P/E
Price to Book Value
2.74
EV to EBIT
110.75
EV to EBITDA
55.81
EV to Capital Employed
5.30
EV to Sales
6.51
PEG Ratio
NA
Dividend Yield
0.32%
ROCE (Latest)
4.78%
ROE (Latest)
3.23%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -5.56% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 3.29 times

-23What is not working for the Company
NET PROFIT(HY)

At CNY -0.76 MM has Grown at -101.36%

ROCE(HY)

Lowest at 3.35%

NET SALES(Q)

Lowest at CNY 94.55 MM

Here's what is working for Sinotherapeutics, Inc.

Inventory Turnover Ratio
Highest at 3.29 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by -5.56% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sinotherapeutics, Inc.

Net Profit
At CNY -0.76 MM has Grown at -101.36%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (CNY MM)

Net Sales
At CNY 94.55 MM has Fallen at -15.31%
over average net sales of the previous four periods of CNY 111.64 MM
MOJO Watch
Near term sales trend is very negative

Net Sales (CNY MM)

Net Sales
Lowest at CNY 94.55 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)